Anika Completes Divestiture of Parcus Medical

Core Insights - Anika Therapeutics has completed the divestiture of its Parcus Medical business to Medacta Group SA, marking a significant step in its strategic review process [1][3] - The company aims to concentrate on its core hyaluronic acid technology and expand its Regenerative Solutions portfolio following the sale [2][3] Company Overview - Anika Therapeutics, Inc. is a leader in Osteoarthritis Pain Management and Regenerative Solutions, focusing on early intervention orthopedics [5] - The company specializes in minimally invasive products that leverage hyaluronic acid and implant solutions to enhance active living for patients globally [5] Transaction Details - The sale of Parcus Medical was finalized on March 7, 2025, for an undisclosed amount, with cash consideration received at closing [3] - Anika and Medacta have agreed to collaborate for a smooth transition post-sale for all stakeholders involved [3][4]